We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Delayed Seizure Control in Focal Epilepsy: Insights from the Human Epilepsy Project

MedXY Editorial Team•Oct 5, 2025•Neurology
antiseizure medicationsfocal epilepsyseizure controltreatment resistance

Highlight

  • Most patients with newly diagnosed focal epilepsy continue to experience seizures for at least one year after starting antiseizure medication (ASM) therapy.
  • About 23% of patients develop treatment resistance within the first year, as defined by failure to respond to two adequate ASM trials.
  • Median time to seizure freedom is approximately 12 months, indicating a prolonged adjustment period necessary for optimal seizure control.
  • Prognostic factors for resistance include a history of psychiatric disorders and high pretreatment seizure frequency.

Study Background and Disease Burden

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Paternal Valproate Exposure and Offspring Neurodevelopmental Outcomes: A Comprehensive Review of Current EvidenceThis review synthesizes evidence on paternal valproate exposure and offspring neurodevelopmental risks, highlighting recent large cohort data that challenge prior concerns of increased neurodevelopmental disorders or congenital malformationAug 24, 2026Balancing Risks: Safety Profiles of Antiseizure Medications in Epilepsy Patients on Direct Oral AnticoagulantsThis study reveals distinct thromboembolic, bleeding, and mortality risks based on antiseizure medication selection in epilepsy patients receiving direct oral anticoagulants, highlighting the critical role of ASM choice on patient safety anAug 18, 2026Pluralistic Model Proposed for Schizophrenia Spectrum: Beyond DopamineA new narrative review synthesizing evidence from 1980 to 2025 argues that schizophrenia spectrum disorders cannot be explained solely by dopaminergic dysfunction. The authors propose a pluralistic model involving multiple neurochemical and cellular processes, with implications for treatment development and biomarker-based stratification.Jul 24, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Optimal Sleep Duration Mitigates Cognitive Decline and Dementia Risk in Focal Epilepsy: Insights from the UK Biobank Study
A UK Biobank study reveals that optimal sleep (6-8 hours) improves executive function and reduces dementia risk in focal epilepsy patients, with effects surpassing those in stroke patients. Nonoptimal sleep exacerbates cognitive deficits up
Apr 25, 2026
Cenobamate Outperforms Brivaracetam, Lacosamide, and Perampanel in Real-World Focal Epilepsy ManagementA large multicenter real-world study indicates that cenobamate provides superior effectiveness and seizure freedom rates compared to brivaracetam, lacosamide, and perampanel in adults with drug-resistant focal epilepsy, despite a higher incFeb 10, 2026
Do Behavioural, Self-Management, and Service Delivery Models Improve Outcomes in Adults with Epilepsy?A Cochrane review finds limited and low- to moderate-certainty evidence that behavioural, self-management, or service delivery interventions improve seizure control or quality of life in adults with epilepsy.Dec 17, 2025